DEVELOPMENT OF NOVEL THERAPEUTICS TO PREVENT OR TREAT PREECLAMPSIA
Grant number: 1146128 | Funding period: 2018 - 2021
Preeclampsia, a major pregnancy complication, affects ~3-8% of pregnancies. There is no cure. We have developed new strategies to tackle the disease, including delivery of agents specifically to the placenta and repurposing drugs safe in pregnancy. We will test whether these strategies can quench disease in models developed in our laboratory, and examine samples from women who participated in clinical trial to treat preeclampsia. This offers new possibilities in the management of preeclampsia.
Related publications (12)
DAAM2 is elevated in the circulation and placenta in pregnancies complicated by fetal growth restriction and is regulated by hypoxia
Natasha de Alwis, Sally Beard, Natalie K Binder, Natasha Pritchard, Tu'uhevaha J Kaitu'u-Lino, Susan P Walker, Owen Stock, Katie Groom, Scott Petersen, Amanda Henry, Joanne M Said, Sean Seeho, Stefan C Kane, Lisa Hui, Stephen Tong, Natalie J Hannan
Previously, we identified increased maternal circulating DAAM2 mRNA in pregnancies complicated by preterm fetal growth restriction..
Nanoparticles in pregnancy: the next frontier in reproductive therapeutics.
Natasha Pritchard, Tu'uhevaha Kaitu'u-Lino, Lynda Harris, Stephen Tong, Natalie Hannan
BACKGROUND: Nanotechnology involves the engineering of structures on a molecular level. Nanomedicine and nano-delivery systems hav..
Circulating Tissue Factor Pathway Inhibitor (TFPI) is increased preceding preeclampsia diagnosis and in established preeclampsia
Teresa M MacDonald, Stephen Tong, Jenny Myers, Ping Cannon, Nguyen Tuong-Vi, Emerson Keenan, Elizabeth Murray, Alesia Harper, Natasha Pritchard, Natalie J Hannan, Kirsten M Dane, Anna L Middleton, Valerie P Kyritsis, Susan P Walker, Tu'uhevaha J Kaitu'u-Lino
INTRODUCTION: Tissue Factor Pathway Inhibitor (TFPI) is a part of the extrinsic coagulation pathway, and highly expressed in the p..
MicroRNAs 363 and 149 are differentially expressed in the maternal circulation preceding a diagnosis of preeclampsia
Carole-Anne Whigham, Teresa M MacDonald, Susan P Walker, Richard Hiscock, Natalie J Hannan, Natasha Pritchard, Ping Cannon, Vi Nguyen Tuong, Manisha Miranda, Stephen Tong, Tu'uhevaha J Kaitu'u-Lino
Preeclampsia is a pregnancy complication associated with angiogenic dysbalance, maternal endothelial dysfunction and end-organ inj..
Pravastatin, proton-pump inhibitors, metformin, micronutrients, and biologics: new horizons for the prevention or treatment of preeclampsia.
Stephen Tong, Tu'uhevaha J Kaitu'u-Lino, Roxanne Hastie, Fiona Brownfoot, Catherine Cluver, Natalie Hannan
There has been increasing research momentum to identify new therapeutic agents for the prevention or treatment of preeclampsia, dr..
Aurora kinase mRNA expression is reduced with increasing gestational age and in severe early onset fetal growth restriction
Sally Beard, Natasha Pritchard, Natalie Binder, Karen Schindler, Natasha De Alwis, Tu'uhevaha J Kaitu'u-Lino, Stephen Tong, Natalie J Hannan
INTRODUCTION: Oxidative damage and biochemical ageing are implicated in placental dysfunction and potentially fetal death. Cellula..
Circulating mRNAs are differentially expressed in pregnancies with severe placental insufficiency and at high risk of stillbirth
Natalie J Hannan, Owen Stock, Rebecca Spencer, Clare Whitehead, Anna L David, Katie Groom, Scott Petersen, Amanda Henry, Joanne M Said, Sean Seeho, Stefan C Kane, Lavinia Gordon, Sally Beard, Kantaraja Chindera, Smita Karegodar, Richard Hiscock, Natasha Pritchard, Tu'uhevaha J Kaitu'u-Lino, Susan P Walker, Stephen Tong
Background Fetuses affected by placental insufficiency do not receive adequate nutrients and oxygenation, become growth restricted..
Circulating SPINT1 is a biomarker of pregnancies with poor placental function and fetal growth restriction
Tu'uhevaha J Kaitu'u-Lino, Teresa M MacDonald, Ping Cannon, Nguyen Tuong-Vi, Richard J Hiscock, Nick Haan, Jenny E Myers, Roxanne Hastie, Kirsten M Dane, Anna L Middleton, Intissar Bittar, Amanda N Sferruzzi-Perri, Natasha Pritchard, Alesia Harper, Natalie J Hannan, Valerie Kyritsis, Nick Crinis, Lisa Hui, Susan P Walker, Stephen Tong
Purpose To investigate the relationship between patient-reported outcome (PRO) questionnaire responses and time to late age-relate..
Pravastatin as the statin of choice for reducing pre-eclampsia-associated endothelial dysfunction
Natasha de Alwis, Sally Beard, Yeukai T Mangwiro, Natalie K Binder, Tu'uhevaha J Kaitu'u-Lino, Fiona C Brownfoot, Stephen Tong, Natalie J Hannan
OBJECTIVES: There is avid interest in pravastatin as a therapeutic intervention for pre-eclampsia, however little is known on stat..
Death associated protein kinase 1 (DAPK-1) is increased in preeclampsia
Cameron Yung, Teresa M MacDonald, Susan P Walker, Ping Cannon, Alesia Harper, Natasha Pritchard, Natalie J Hannan, Tu'uhevaha J Kaitu'u-Lino, Stephen Tong
INTRODUCTION: Death associated protein kinase-1 (DAPK-1) is highly expressed in the placenta relative to all other human tissues. ..
The untapped potential of placenta-enriched molecules for diagnostic and therapeutic development
Carole-Anne Whigham, Teresa M MacDonald, Susan P Walker, Natalie J Hannan, Stephen Tong, Tu'uhevaha J Kaitu'u-Lino
Pregnancy complications such as fetal growth restriction and preeclampsia are diseases with limited biomarkers for prediction, and..
Circulating GATA2 mRNA is decreased among women destined to develop preeclampsia and may be of endothelial origin
Carole-Anne Whigham, Teresa M MacDonald, Susan P Walker, Natasha Pritchard, Natalie J Hannan, Ping Cannon, Vi Nguyen Tuong, Roxanne Hastie, Stephen Tong, Tu'uhevaha J Kaitu'u-Lino